Artifactual isoform profile modification following treatment of human plasma or serum with protease inhibitor, monitored by 2-dimensional electrophoresis and mass spectrometry

BioTechniques

Volumn 39, Issue 2, 2005, Pages 239-247

  Schuchard, Mark D ^a   Mehigh, Richard J ^a   Cockrill, Steven L ^a   Lipscomb, George T ^a   Stephan, Jonathan D ^a   Wildsmith, Justin ^a   Valdes Camin, Rafael ^a   Kappel, William K ^a   Rai, Alex J ^b   Scott, Graham B I ^a  

^a Sigma Aldrich Co   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFACTUAL ISOFORM PROFILE MODIFICATION; ISOELECTRIC POINT; PROTEASE INHIBITOR; TYROSINE RESIDUES;

BIOMEDICAL ENGINEERING; ELECTROPHORESIS; GELS; PLASMAS; POLYPEPTIDES; RANDOM PROCESSES;

ENZYME INHIBITION;

4 (2 AMINOETHYL)BENZENESULFONYL FLUORIDE; ALBUMIN; APOLIPOPROTEIN A1; IMMUNOGLOBULIN G; PLASMA PROTEIN; SERINE PROTEINASE INHIBITOR; ISOPROTEIN; PROTEINASE INHIBITOR;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; HUMAN; ISOELECTRIC POINT; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEIN MODIFICATION; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING; ARTIFACT; BLOOD ANALYSIS; CHEMISTRY; EVALUATION; GENE EXPRESSION PROFILING; LABORATORY DIAGNOSIS; MASS SPECTROMETRY; METHODOLOGY; PLASMA; SERUM; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ARTIFACTS; BLOOD CHEMICAL ANALYSIS; BLOOD PROTEINS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION PROFILING; MASS SPECTROMETRY; PLASMA; PROTEASE INHIBITORS; PROTEIN ISOFORMS; SERUM; SPECIMEN HANDLING;

EID: 25644460465     PISSN: 07366205     EISSN: None     Source Type: Journal    
DOI: 10.2144/05392RR01     Document Type: Article

References (11)

1. Altland, K., T. Roeder, H.M. Jakin, H.G. Zimmer, and V. Neuhoff. 1982. Demonstration of alpha 1-acid glycoprotein (orosomucoid) by double one-dimensional slab gel electrophoresis: evidence for intra- and interindividual variability of the microheterogeneity pattern in health and disease. Clin. Chem. 28:1000-1010.
2. Janckila, A.J., Y.R. Nakasato, D.H. Neustadt, and L.T. Yam. 2003. Disease-specific expression of tartrate-resistant acid phosphatase isoforms. J. Bone Miner. Res. 18:1916-1919.
3. Johnson, P.J. 2001. The role of serum alphafetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin. Liver Dis. 5:145-159.
4. Thompson, P.A. and C. Ambrosone. 2000. Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J. Natl. Cancer Inst. Monogr. 27:125-134.
5. Omenn, G.S. 2004. The Human Proteome Organization Plasma Proteome Project Pilot Phase: reference specimens, technology platform comparisons, and standardized data submissions and analyses. Proteomics 4:1235-1240.
6. Rai, A.J., C.A. Gelfand, B.C. Haywood, D. Warunek, C. Skobe, M.D. Schuchard, R.J. Mehigh, S.L. Cockrill, et al. Human Proteome Organization-Plasma Proteome Project Specimen Collection and Handling Committee Report: towards the standardization of parameters for plasma proteome samples. Proteomics (In press).
7. Mintz, G.R. 1993. Technical note: an irreversible serine protease inhibitor. BioPharm. 6:34-38.
8. Sweeney, B., K. Proudfoot, A.H. Parton, L.M. King, P. Slocombe, and M.J. Perry. 1997. Purification of the T-cell receptor ζ-chain: covalent modification by 4-(2-aminoethyl)-benzenesulfonyl fluoride. Anal. Biochem. 245:107-109.
9. Bergen, H.R., 3rd, M.G. Klug, M.E. Bolander, and D.C. Muddiman. 2004. Informed use of proteolytic inhibitors in biomarker discovery. Rapid Commun. Mass Spectrom. 18:1001-1002.
10. Chu, T.M. and E. Kawinski. 1998. Plasmin, substilisin-like endoproteases, tissue plasminogen activator, and urokinase plasminogen activator are involved in activation of latent TGF-beta 1 in human seminal plasma. Biochem. Biophys. Res. Commun. 253:128-134.
11. Dentan, C., A.D. Tselepis, M.J. Chapman, and E. Ninio. 1996. Pefabloc, 4-[2-aminoethyl] benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase. Biochim. Biophys. Acta 1299:353-357.